search
Back to results

Fructose Consumption and Metabolic Dysregulation

Primary Purpose

Central Obesity, Hypertriglyceridemia

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Fructose
Sponsored by
Marja-Riitta Taskinen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Central Obesity focused on measuring fructose, hypertriglyceridemia, postprandial lipids, de novo lipogenesis, stable isotopes

Eligibility Criteria

20 Years - 60 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Body mass index 27-40
  • Waist > 96 cm
  • Age 20-60 years
  • Male

Exclusion Criteria:

  • Smoking
  • Active health problems
  • Contraindications to MRI scanning
  • Bleeding tendency
  • Abnormal liver or renal function tests
  • Type 2 diabetes
  • Evidence of metabolic or viral liver disease
  • Alcohol intake > 21 units per week
  • Chronic medication except ones needed for stable hypertension

Sites / Locations

  • Université Laval
  • Helsinki University Central Hospital, Biomedicum
  • University of Naples, Federico II, and Faculty of Medicine
  • Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

After fructose feeding

Arm Description

After 3 month fructose diet 75 g/day

Outcomes

Primary Outcome Measures

TG Plasma AUC
Before vs. after fructose challenge: Triglycerides (TG) plasma Area Under Curve (AUC)
B48 Plasma AUC
Before vs. after fructose challenge: apolipoprotein (apo)B48 plasma Area Under Curve (AUC)
TG Plasma iAUC
Before vs. after fructose challenge:Triglycerides (TG) plasma incremental Area Under Curve (iAUC)

Secondary Outcome Measures

DNL
Before vs. after fructose challenge: de novo lipogenesis (DNL)
ApoC-III
Before vs. after fructose challenge: Apolipoprotein C-III (ApoC-III)
β-OH Butyrate
Before vs. after fructose challenge: beta-OH butyrate (β-OH butyrate)
Liver Fat
Before vs. after fructose challenge

Full Information

First Posted
September 28, 2011
Last Updated
May 19, 2021
Sponsor
Marja-Riitta Taskinen
Collaborators
Sahlgrenska University Hospital, Sweden, Lund University, University of Naples, Laval University
search

1. Study Identification

Unique Protocol Identification Number
NCT01445730
Brief Title
Fructose Consumption and Metabolic Dysregulation
Official Title
Fructose Consumption Aggravates Dysregulation of Postprandial Lipid Metabolism in Obese Hypertriglyceridemic Men With High Cardiometabolic Risk Profile and Associates With Liver Fat Deposition
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Marja-Riitta Taskinen
Collaborators
Sahlgrenska University Hospital, Sweden, Lund University, University of Naples, Laval University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be activated by fructose independently of insulin. However, it is still controversial whether fructose consumption increases DNL in man to the extent that it induces metabolic disturbances. Animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. The role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. The critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.
Detailed Description
Detailed description: Study subjects will participate to studies 1-4 before and 3 m after fructose diet: An oral fat load or a kinetic study with stable isotopes combined with an oral fat load. Determination of liver, subcutaneous and intra-abdominal fat. (Proton magnetic resonance spectroscopy ) Lipolytic enzymes, advanced lipid analysis, fat biopsies and genetic studies and gut microbiota profiling Oral glucose tolerance test and analysis of incretins and inflammatory biomarkers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Central Obesity, Hypertriglyceridemia
Keywords
fructose, hypertriglyceridemia, postprandial lipids, de novo lipogenesis, stable isotopes

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
82 (Actual)

8. Arms, Groups, and Interventions

Arm Title
After fructose feeding
Arm Type
Experimental
Arm Description
After 3 month fructose diet 75 g/day
Intervention Type
Dietary Supplement
Intervention Name(s)
Fructose
Intervention Description
3 month fructose diet 75 g/day
Primary Outcome Measure Information:
Title
TG Plasma AUC
Description
Before vs. after fructose challenge: Triglycerides (TG) plasma Area Under Curve (AUC)
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Title
B48 Plasma AUC
Description
Before vs. after fructose challenge: apolipoprotein (apo)B48 plasma Area Under Curve (AUC)
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Title
TG Plasma iAUC
Description
Before vs. after fructose challenge:Triglycerides (TG) plasma incremental Area Under Curve (iAUC)
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Secondary Outcome Measure Information:
Title
DNL
Description
Before vs. after fructose challenge: de novo lipogenesis (DNL)
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Title
ApoC-III
Description
Before vs. after fructose challenge: Apolipoprotein C-III (ApoC-III)
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Title
β-OH Butyrate
Description
Before vs. after fructose challenge: beta-OH butyrate (β-OH butyrate)
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Title
Liver Fat
Description
Before vs. after fructose challenge
Time Frame
Form the baseline (time point 1) to end of treatment at 3 months (time point 2)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Body mass index 27-40 Waist > 96 cm Age 20-60 years Male Exclusion Criteria: Smoking Active health problems Contraindications to MRI scanning Bleeding tendency Abnormal liver or renal function tests Type 2 diabetes Evidence of metabolic or viral liver disease Alcohol intake > 21 units per week Chronic medication except ones needed for stable hypertension
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marja-Riitta Taskinen, Professor
Organizational Affiliation
Helsinki University Central Hospital, Biomedicum
Official's Role
Principal Investigator
Facility Information:
Facility Name
Université Laval
City
Québec
Country
Canada
Facility Name
Helsinki University Central Hospital, Biomedicum
City
Helsinki
ZIP/Postal Code
00290
Country
Finland
Facility Name
University of Naples, Federico II, and Faculty of Medicine
City
Naples
Country
Italy
Facility Name
Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital
City
Gothenburg
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
36040803
Citation
Taskinen MR, Bjornson E, Matikainen N, Soderlund S, Ramo J, Ainola MM, Hakkarainen A, Sihlbom C, Thorsell A, Andersson L, Bergh PO, Henricsson M, Romeo S, Adiels M, Ripatti S, Laakso M, Packard CJ, Boren J. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations. JCI Insight. 2022 Oct 10;7(19):e160607. doi: 10.1172/jci.insight.160607.
Results Reference
derived

Learn more about this trial

Fructose Consumption and Metabolic Dysregulation

We'll reach out to this number within 24 hrs